# Clinical Trials Data EGFR - Document 50

# Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)

## Clinical Trial: https://clinicaltrials.gov/study/NCT01391260

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Histologically confirmed diagnosis of non-squamous NSCLC; Stage \u2162A-\u2162B(not suitable for surgery) or stage \u2163(only single-site single transfer );\n\* Untreated patients, or who completed \u2264 2 cycles of first-line chemotherapy (chemotherapy regimen: paclitaxel, docetaxel + cisplatin) within the previous month;\n\* Patients with tumor EGFR mutation positive (exon 19 deletion mutation or exon 21 L858R substitution mutation);\n\* Patients must be informed of the investigational nature of the study and must sign an informed consent form;\n\* Presence of at least one measurable/evaluable according to RECIST criteria.\n\* ECOG performance Status 0-2 ;\n\* Patients must have a life expectancy \\> 12 weeks;\n\* Patients with laboratory values as follows:WBC\\>4.0 x 109/L; ANC\u22651.5 x 109/L; PLT\u2265100 x 109/L; HGB\u226510 g/dL; CR\u22641.5 x ULN; TBIL\\<1.5 x ULN; AST and ALT\u22641.5 x ULN; LDH\u22641.5 x ULN; AKP\u22645 x ULN;\n\* FEV 1\u22651.0L and \\>50% Corresponding normal values;\n\* Patient candidate to standard platinum-based chemotherapy;\n\* Patients must be nonpregnant and non-lactating.Patients of childbearing potential must implement an effective method of contraception during the study. All female Patients, except those who are postmenopausal or surgically sterilized, must have a negative pre-study serum or urine pregnancy test.\n\nExclusion Criteria:\n\n\* Any evidence of clinically active interstitial lung disease;\n\* Diagnosis of any other malignancy during the last 5 years, except for in situ carcinoma of cervix uterine and squamous cell carcinoma of the skin\uff1b\n\* Pregnancy or lactating\uff1b\n\* Serious concomitant infection;\n\* MI within preceding 6 months or symptomatic heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmia;\n\* As judged by the investigator, any evidence of severe or uncontrolled systemic disease (eg, unstable or uncompensated respiratory, cardiac, hepatic, or renal disease);\n\* Patients who are not suitable to participate in the trial according to researchers.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria, a patient with an EGFR gene mutation would be eligible for this clinical trial, provided they meet the other inclusion criteria and do not meet any of the exclusion criteria. Specifically, having a tumor with an EGFR mutation (exon 19 deletion mutation or exon 21 L858R substitution mutation) is listed as one of the inclusion criteria. Thus, having this mutation makes the patient eligible in terms of this requirement. However, the patient's overall eligibility would also depend on the other factors outlined in the inclusion and exclusion criteria.